# Efficacy and Safety of Grazoprevir (+) Uprifosbuvir (+) Ruzasvir (MK-3682B) (MK-5172 + MK-3682 + MK-8408) Fixed Dose Combination in Chronic HCV Participants Failing Prior Antiviral Treatment (MK-3682-021)

> **NCT02613403** · PHASE2 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 94 (actual)

## Conditions studied

- Hepatitis
- Hepatitis C
- Digestive System Diseases
- Flaviviridae Infections
- Hepatitis, Viral, Human
- Liver Diseases
- RNA Virus Infections
- Virus Diseases

## Interventions

- **DRUG:** MK-3682B
- **DRUG:** Ribavirin

## Key facts

- **NCT ID:** NCT02613403
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-12-10
- **Primary completion:** 2017-01-09
- **Final completion:** 2017-03-27
- **Target enrollment:** 94 (ACTUAL)
- **Last updated:** 2024-05-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02613403

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02613403, "Efficacy and Safety of Grazoprevir (+) Uprifosbuvir (+) Ruzasvir (MK-3682B) (MK-5172 + MK-3682 + MK-8408) Fixed Dose Combination in Chronic HCV Participants Failing Prior Antiviral Treatment (MK-3682-021)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02613403. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*